10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. The company reported quarterly sales of $151.654 million which missed the analyst consensus estimate of $158.632 million by 4.40 percent. This is a 1.30 percent decrease over sales of $153.644 million the same period last year.